Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

Open Access 01-06-2020 | Photodynamic Therapy | Retinal Disorders

Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy

Authors: Thomas J. van Rijssen, Sumit Randhir Singh, Elon H. C. van Dijk, Mohammed A. Rasheed, Kiran Kumar Vupparaboina, Camiel J. F. Boon, Jay Chhablani

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 6/2020

Abstract

Purpose

To assess whether treatment of chronic central serous chorioretinopathy (cCSC) with photodynamic therapy (PDT) and high-density subthreshold micropulse laser (HSML) results in choroidal vascularity index (CVI) changes that may account for the treatment effect.

Methods

Patients with cCSC were prospectively included and analyzed. Patients received either half-dose PDT or HSML treatment. CVI of the affected and unaffected eye was obtained before treatment, 6 to 8 weeks after treatment, and 7 to 8 months after treatment.

Results

At baseline, 29 eyes (29 patients) were included both in the PDT and in the HSML group. The mean (± standard deviation) CVI change in the HSML group between before PDT and 6 to 8 weeks after PDT was − 0.009 ± 0.032 (p = 0.127), whereas this was 0.0025 ± 0.037 (p = 0.723) between the visit before PDT and final visit. The patients in the PDT group had a CVI change of − 0.0025 ± 0.037 (p = 0.723) between the visit before PDT and first visit after PDT, and a mean CVI change of − 0.013 ± 0.038 (p = 0.080) between the visit before PDT and final visit. There was no significant correlation between CVI and BCVA at the measured time points, in both the HSML group (p = 0.885), and in the PDT group (p = 0.904). Moreover, no significant changes in CVI occurred in the unaffected eye at any time point.

Conclusions

PDT and HSML do not significantly affect CVI, and therefore a CVI change may not be primarily responsible for the treatment effect. The positive treatment effect of both interventions may rely on other mechanisms, such as an effect on choriocapillaris and/or retinal pigment epithelium function.

Gass JD (1967) Pathogenesis of disciform detachment of the neuroepithelium: II. Idiopathic central serous choroidopathy. Am J Ophthalmol 63(3):587/515–615/543. https://doi.org/10.1016/0002-9394(67)90027-X CrossRef

Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F (2015) PACHYCHOROID: an inherited condition? Retina 35(1):10–16CrossRef

Bouzas EA, Scott MH, Mastorakos G, Chrousos GP, Kaiser-Kupfer MI (1993) Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol 111(9):1229–1233CrossRef

Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118CrossRef

Gemenetzi M, De Salvo G, Lotery A (2010) Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye 24(12):1743CrossRef

Mehta PH, Meyerle C, Sivaprasad S, Boon C, Chhablani J (2017) Preferred practice pattern in central serous chorioretinopathy. Br J Ophthalmol 101(5):587–590. https://doi.org/10.1136/bjophthalmol-2016-309247 CrossRefPubMed

Chan W-M, Lai TY, Lai RY, Liu DT, Lam DS (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115(10):1756–1765CrossRef

Piccolino FC, Eandi CM, Ventre L, De La Longrais RCR, Grignolo FM (2003) Photodynamic therapy for chronic central serous chorioretinopathy. Retina 23(6):752–763CrossRef

Dhirani NA, Yang Y, Somani S (2017) Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy. Clin Ophthalmol (Auckland, NZ) 11:2145–2149. https://doi.org/10.2147/opth.s151933 CrossRef

10.

Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S (2014) Photodynamic therapy for central serous chorioretinopathy. Eye (London, England) 28(8):944–957. https://doi.org/10.1038/eye.2014.134 CrossRef

11.

Arsan A, Kanar HS, Sonmez A (2018) Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up. Eye (London, England) 32(4):726–733. https://doi.org/10.1038/eye.2017.293 CrossRef

12.

Maruko I, Koizumi H, Hasegawa T, Arakawa H, Iida T (2017) Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy. PLoS One 12(8):e0184112CrossRef

13.

Ricci F, Missiroli F, Regine F, Grossi M, Dorin G (2009) Indocyanine green enhanced subthreshold diode-laser micropulse photocoagulation treatment of chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 247(5):597–607. https://doi.org/10.1007/s00417-008-1014-1 CrossRefPubMed

14.

Chen S-N, Hwang J-F, Tseng L-F, Lin C-J (2008) Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology 115(12):2229–2234CrossRef

15.

Breukink MB, den Hollander AI, Keunen JE, Boon CJ, Hoyng CB (2014) The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Acta Ophthalmol 92(6):e488–e490. https://doi.org/10.1111/aos.12392 CrossRefPubMed

16.

Singh RP, Sears JE, Bedi R, Schachat AP, Ehlers JP, Kaiser PK (2015) Oral eplerenone for the management of chronic central serous chorioretinopathy. Int J Ophthalmol 8(2):310–314. https://doi.org/10.3980/j.issn.2222-3959.2015.02.17 CrossRefPubMedPubMedCentral

17.

Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F (2013) Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina (Philadelphia, Pa) 33(10):2096–2102. https://doi.org/10.1097/IAE.0b013e318297a07a CrossRef

18.

van Rijssen TJ, van Dijk EHC, Dijkman G, Boon CJF (2018) Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 256(8):1395–1402. https://doi.org/10.1007/s00417-018-4003-z CrossRefPubMedPubMedCentral

19.

van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S, Hoyng CB, Piccolino FC, Chhablani JK, Lai TYY, Lotery AJ, Larsen M, Holz FG, Freund KB, Yannuzzi LA, Boon CJF (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770. https://doi.org/10.1016/j.preteyeres.2019.07.003 CrossRefPubMed

20.

van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF (2018) Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology 125(10):1547–1555. https://doi.org/10.1016/j.ophtha.2018.04.021 CrossRefPubMed

21.

Breukink MB, Downes SM, Querques G, van Dijk EH, den Hollander AI, Blanco-Garavito R, Keunen JE, Souied EH, MacLaren RE, Hoyng CB (2015) Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial. Trials 16(1):419CrossRef

22.

Agrawal R, Gupta P, Tan K-A, Cheung CMG, Wong T-Y, Cheng C-Y (2016) Choroidal vascularity index as a measure of vascular status of the choroid: measurements in healthy eyes from a population-based study. Sci Rep 6:21090CrossRef

23.

Sonoda S, Sakamoto T, Yamashita T, Shirasawa M, Uchino E, Terasaki H, Tomita M (2014) Choroidal structure in normal eyes and after photodynamic therapy determined by binarization of optical coherence tomographic images. Invest Ophthalmol Vis Sci 55(6):3893–3899. https://doi.org/10.1167/iovs.14-14447 CrossRefPubMed

24.

Sonoda S, Sakamoto T, Yamashita T, Uchino E, Kawano H, Yoshihara N, Terasaki H, Shirasawa M, Tomita M, Ishibashi T (2015) Luminal and stromal areas of choroid determined by binarization method of optical coherence tomographic images. Am J Ophthalmol 159(6):1123–1131.e1121. https://doi.org/10.1016/j.ajo.2015.03.005 CrossRefPubMed

25.

Lee M, Lee H, Kim HC, Chung H (2018) Changes in stromal and luminal areas of the choroid in pachychoroid diseases: insights into the pathophysiology of pachychoroid diseases. Invest Ophthalmol Vis Sci 59(12):4896–4908. https://doi.org/10.1167/iovs.18-25018 CrossRefPubMed

26.

Agrawal R, Chhablani J, Tan K-A, Shah S, Sarvaiya C, Banker A (2016) Choroidal vascularity index in central serous chorioretinopathy. Retina 36(9):1646–1651CrossRef

27.

Agrawal R, Wei X, Goud A, Vupparaboina KK, Jana S, Chhablani J (2017) Influence of scanning area on choroidal vascularity index measurement using optical coherence tomography. Acta Ophthalmol 95(8):e770–e775. https://doi.org/10.1111/aos.13442 CrossRefPubMed

28.

Vupparaboina KK, Nizampatnam S, Chhablani J, Richhariya A, Jana S (2015) Automated estimation of choroidal thickness distribution and volume based on OCT images of posterior visual section. Comput Med Imaging Graph 46(Pt 3):315–327. https://doi.org/10.1016/j.compmedimag.2015.09.008 CrossRefPubMed

29.

Vupparaboina KK, Dansingani KK, Goud A, Rasheed MA, Jawed F, Jana S, Richhariya A, Freund KB, Chhablani J (2018) Quantitative shadow compensated optical coherence tomography of choroidal vasculature. Sci Rep 8(1):6461. https://doi.org/10.1038/s41598-018-24577-8 CrossRefPubMedPubMedCentral

30.

Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58(2):103–126CrossRef

31.

Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF (2010) Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 117(9):1792–1799. https://doi.org/10.1016/j.ophtha.2010.01.023 CrossRefPubMed

32.

Spaide RF, Koizumi H, Pozonni MC (2008) Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 146(4):496–500CrossRef

33.

Imamura Y, Fujiwara T, Margolis R, Spaide RF (2009) Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina (Philadelphia, Pa) 29(10):1469–1473. https://doi.org/10.1097/IAE.0b013e3181be0a83 CrossRef

34.

Park W, Kim M, Kim RY, Park YH (2019) Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence. Graefes Arch Clin Exp Ophthalmol. https://doi.org/10.1007/s00417-019-04426-8

35.

Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB (2018) Pachychoroid disease. Eye (London, England) 33(1):14–33. https://doi.org/10.1038/s41433-018-0158-4 CrossRef

36.

van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Blanco-Garavito R, Souied EH, Keunen JEE, MacLaren RE, Querques G, Fauser S, Downes SM, Hoyng CB, Boon CJF (2019) Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE trial report no. 3. Am J Ophthalmol 205:1–10. https://doi.org/10.1016/j.ajo.2019.03.025 CrossRefPubMed

Title: Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy
Authors: Thomas J. van Rijssen
Sumit Randhir Singh
Elon H. C. van Dijk
Mohammed A. Rasheed
Kiran Kumar Vupparaboina
Camiel J. F. Boon
Jay Chhablani
Publication date: 01-06-2020
Publisher: Springer Berlin Heidelberg
Keywords: Photodynamic Therapy
Laser
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 6/2020
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-020-04619-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2020

Influence of epinephrine contained in local anesthetics on upper eyelid height in transconjunctival blepharoptosis surgery

Treatment of retinopathy of prematurity (ROP) outside International Classification of ROP (ICROP) guidelines

Quantitative assessment of the retinal microvasculature and choriocapillaris in myopic patients using swept-source optical coherence tomography angiography

Minzhong Yu, Donnell Creel, Alessandro Iannaccone: Handbook of clinical electrophysiology of vision, 1st edition

Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic

Regulatory T cells and IL-17A levels in noninfectious uveitis